Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor

ABSTRACT: Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor

PROVIDER: PRJNA573906 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10173820_1.fastq.gz	Fastqsanger.gz
	SRR10173820_2.fastq.gz	Fastqsanger.gz
	SRR10173821_1.fastq.gz	Fastqsanger.gz
	SRR10173821_2.fastq.gz	Fastqsanger.gz
	SRR10173822_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor

Project description:IDH1 mutations are closely related to the development and progression of various human cancers, such as glioblastoma, sarcoma, and acute myeloid leukemia. By screening dozens of reported natural compounds using both wild-type and mutant IDH1 enzymatic assays, we discovered Licochalcone A is a selective inhibitor to the R132C-mutant IDH1 with an IC50 value of 5.176 μM, and inhibits the proliferation of HT1080 cells with an IC50 value of 10.75 μM. Suggested by the molecular docking results, Licochalcone A might occupy the allosteric pocket between the two monomers of IDH1 homodimer, and the R132H mutation was unfavorable for the binding of Licochalcone A with the IDH1 protein, as compared to the R132C mutation. Revealed by the RNA-Seq data analysis, the Cell Cycle pathway was the most over-represented pathway for HT1080 cells treated with Licochalcone A. Consistent with these results, Licochalcone A induced apoptosis and cell cycle arrest of HT1080 cells, while it showed minimal effect against the proliferation of normal RCTEC cells. The discovery of Licochalcone A as a mutation-selective IDH1 inhibitor can serve as a promising starting point for the development of mutation-selective anti-tumor lead compounds that target IDH1.

2019-10-24 | GSE137934 | GEO

RepliSeq of HT-1080 cell line

2014-07-31 | GSE58907 | GEO

RepliSeq of HT-1080 cell line

Project description:Analysis of replication timing by RepliSeq of HT-1080 Human Connective Tissue Fibrosarcoma Cells. HT-1080 subclone +4 cell line as described in “Human gene targeting favors insertions over deletions.” Russell, D.W., and Hirata, R.K. (2008). Hum Gene Ther 19, 907-914. RepliSeq of HT-1080 cell line was used to determine the impact of DNA replication on targeted adeno-associated virus sites by mapping replication forks, which revealed a consistent preference for recombination at target loci transcribed towards an incoming fork.

2014-07-31 | E-GEOD-58907 | biostudies-arrayexpress

Proteomic analysis of HT-1080 cells overexpressing protein ARGLU1

Project description:A proteomic comparison between normal HT-1080 cells and HT-1080 cells that have been stably transfected to overexpress protein arginie and glutamate rich 1 (ARGLU1).

2024-05-13 | PXD046329 | Pride

Development of gene expression signatures for subconfluent and overconfluent HT-1080 fibrosarcoma cell line

Project description:We investigated the changes in gene expression profile between subconfluent (80%) and overconfluent HT-1080 fibrosarcoma cell line. We have employed whole genome microarray expression profiling as a discovery platform to identify genes expression profiles in HT-1080 cells. Total RNAs from subconfluent (HT-1080_80%) and overconfluent (HT-1080_overconfluent) HT-1080 cells were harvested and subjected to the microarray analysis.

2015-06-04 | E-GEOD-69534 | biostudies-arrayexpress

Development of gene expression signatures for subconfluent and overconfluent HT-1080 fibrosarcoma cell line

Project description:We investigated the changes in gene expression profile between subconfluent (80%) and overconfluent HT-1080 fibrosarcoma cell line.

2015-06-04 | GSE69534 | GEO

Genes regulated in HT-1080 cells after 24 hours of treatment with IRAK4 inhibitor

Project description:Analysis of HT-1080 fibrosarcoma cells transcriptome following 24 hours treatment with IRAK4 inhibitor was performed. Results provide insight into mode of action of IRAK4 inhibitor under study. Project co-financed from European Regional Development Fund under The Operational Program Innovative Economy, 2007-2013, measure 1.4 (UDA-POIG.01.04.00-12-049/11-00)

2018-11-24 | GSE122845 | GEO

Genes regulated in HT-1080 cells after 4 hours of treatment with IRAK4 inhibitor

Project description:Analysis of HT-1080 fibrosarcoma cells transcriptome following 4 hours treatment with IRAK4 inhibitor was performed. Results provide insight into mode of action of IRAK4 inhibitor under study. Project co-financed from European Regional Development Fund under The Operational Program Innovative Economy, 2007-2013, measure 1.4 (UDA-POIG.01.04.00-12-049/11-00)

2018-11-24 | GSE122844 | GEO

Aqueous and DMSO extracts from Annona muricata leaves protect from ferroptosis to both HT-1080 fibrosarcoma cells and HMEC-1 endothelial cells.

Project description:Graviola (Annona muricata) is a tropical plant with many traditional ethnobotanic uses and pharmacologic applications. A metabolomic study of both aqueous and DMSO extracts from Annona muricata leaves recently allowed us to identify dozens of bioactive compounds. In the present study, we use a proteomic study to reveal new bioactivities of these leave extracts on both conditioned media and extracts of HT-1080 fibrosarcoma treated cells. Our results reveal the complete sets of deregulated proteins after treatment with aqueous and DMSO extracts from An-nona muricata leaves. Functional enrichment analysis of proteomic data suggests deregulation of cell cycle and iron metabolism, which are experimentally validated. Additional experimental data reveal that these extracts protect from ferroptosis to both HT-1080 fibrosarcoma cells and HMEC-1 endothelial cells.

2023-10-24 | PXD042354 | Pride

Dual-Isotope Lipidomics HT-1080 Ferroptosis

Project description:Full MS dataset from POS and NEG modes from lipidomic extraction of HT-1080 cells. C is control, D is treated with deuterated arachidonic acid (dAA), R is treated with RSL3, and RD is treated with both dAA and RSL3. This dataset accompanies a manuscript titled "Tracking the Fate of Exogenous Arachidonic Acid in Ferroptosis Using Dual-Isotope Labeling Lipidomics" (JASMS, 2023)

2023-06-27 | MSV000092288 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data